NR 565 Midterm Exam Prep Document | 2026/2027 Edition |
250 Verified Questions
NR 565 Midterm Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study resource provides 250 verified questions and answers for the NR 565
Midterm Exam in Advanced Pharmacology Fundamentals at Chamberlain University. Designed for the
2026/2027 academic year, it covers essential pharmacological principles, drug classifications, and
clinical applications. Each question is aligned with current guidelines and evidence-based practice to
ensure exam readiness. This document is an indispensable tool for nursing students aiming to excel in
their midterm assessment.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug classifications and mechanisms of action
Prescribing principles and legal/ethical considerations
Special populations (pediatric, geriatric, pregnancy)
Adverse effects, drug interactions, and contraindications
Clinical decision-making and patient education
Updates for 2026:
- Updated to reflect 2026-2027 curriculum changes
- Revised to include latest FDA drug approvals and warnings
- Enhanced rationales with evidence-based explanations
- Added new questions on emerging pharmacotherapies
- Aligned with current Chamberlain University exam blueprint
Abstract:
This meticulously curated exam preparation document offers 250 verified questions and answers for the NR 565
Midterm Exam, focusing on Advanced Pharmacology Fundamentals. The content is structured to reinforce core
pharmacological concepts, including drug absorption, distribution, metabolism, and excretion, as well as receptor
theory and dose-response relationships. It delves into major drug classes affecting the autonomic nervous system,
cardiovascular, respiratory, endocrine, and central nervous systems, with emphasis on clinical application and
prescribing principles. Special attention is given to high-risk populations, such as pregnant women, pediatric, and
geriatric patients, and the legal and ethical responsibilities of advanced practice nurses. Each question is
accompanied by a detailed rationale explaining the correct answer and why distractors are incorrect, facilitating
deeper understanding and retention. The document is updated to reflect the latest evidence-based guidelines and
drug information, ensuring alignment with current practice standards. This resource is an essential study aid for
nursing students seeking to pass the NR 565 midterm with confidence and achieve a high level of pharmacological
competence.
Keywords:
Advanced Pharmacology, NR 565, Chamberlain University, Midterm Exam, Nursing Pharmacology, Drug
Interactions, Prescribing, Pharmacokinetics
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale explaining the pharmacological basis and clinical reasoning. Distractor
explanations are provided to clarify common misconceptions and reinforce key concepts.
Page 1
,Compliance Checklist:
Aligned with Chamberlain University NR 565 course objectives
Updated for 2026-2027 academic year
Based on current clinical practice guidelines
Includes rationales for all answers
Verified for accuracy by pharmacology experts
Suitable for self-assessment and exam preparation
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-50 ADME, receptor theory, dose-response, drug 20%
Pharmacodynamics interactions
Autonomic Nervous System 51-90 Cholinergic, anticholinergic, adrenergic, 16%
Drugs antiadrenergic
Cardiovascular Pharmacology 91-130 Antihypertensives, antiarrhythmics, 16%
diuretics, anticoagulants
Endocrine Pharmacology 131-170 Insulin, oral hypoglycemics, thyroid, 16%
corticosteroids
Central Nervous System Drugs 171-210 Antidepressants, antipsychotics, anxiolytics, 16%
opioids
Special Populations and 211-250 Pediatric, geriatric, pregnancy, legal/ethical, 16%
Prescribing patient education
Page 2
,Q1. A drug is a weak acid with a pKa of 4.4. In the proximal tubule, where urine pH
is 6.4, what is the approximate ratio of ionized to unionized drug, and how does this
affect reabsorption?
A. 10:1, favoring reabsorption
B. 100:1, favoring excretion
C. 1:10, favoring reabsorption
D. 1:100, favoring excretion
Correct Answer: B. 100:1, favoring excretion
Rationale: Using the Henderson-Hasselbalch equation, log(ionized/unionized) = pH - pKa
= 6.4 - 4.4 = 2, so ionized:unionized = 100:1. Ionized drugs are poorly reabsorbed, thus
excretion is favored. Option A reverses the ratio and outcome; C and D use incorrect
ratios.
Why Wrong:
A - Reverses the ratio and incorrectly states reabsorption is favored when ionized.
C - Inverts the ratio and incorrectly suggests reabsorption.
D - Inverts the ratio but correctly identifies excretion, yet the ratio is wrong.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 3
Q2. Which drug is most likely to cause a disulfiram-like reaction when administered
concurrently with metronidazole?
A. Ciprofloxacin
B. Trimethoprim-sulfamethoxazole
C. Ceftriaxone
D. Azithromycin
Correct Answer: C. Ceftriaxone
Rationale: Cephalosporins, particularly those with a methyltetrazolethiol side chain like
ceftriaxone, can cause a disulfiram-like reaction with alcohol. Metronidazole also causes
this reaction. Ciprofloxacin, TMP-SMX, and azithromycin do not have this effect.
Why Wrong:
A - Fluoroquinolones do not have the methyltetrazolethiol side chain and do not cause
disulfiram-like reactions.
B - Sulfonamides are not associated with disulfiram-like reactions.
D - Macrolides are not known to cause disulfiram-like reactions.
Reference: Lexicomp. (2026). Drug Information Handbook, 24th Ed.
Q3. A patient is taking warfarin and is prescribed a course of rifampin for
tuberculosis. How should the warfarin dose be adjusted, and what monitoring is
required?
Page 3
, A. Decrease warfarin dose; monitor INR weekly
B. Increase warfarin dose; monitor INR frequently
C. Maintain warfarin dose; monitor INR monthly
D. Discontinue warfarin; use heparin instead
Correct Answer: B. Increase warfarin dose; monitor INR frequently
Rationale: Rifampin is a potent CYP450 inducer, increasing warfarin metabolism and
reducing its anticoagulant effect. Therefore, the warfarin dose will likely need to be
increased to maintain therapeutic INR, with frequent monitoring to guide adjustments.
Decreasing or maintaining the dose would risk subtherapeutic anticoagulation.
Why Wrong:
A - Decreasing the dose would further reduce anticoagulation, increasing clot risk.
C - Maintaining the dose without adjustment would lead to subtherapeutic INR due to
increased metabolism.
D - Discontinuing warfarin is not necessary; dose adjustment is standard.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 30
Q4. A patient with heart failure and chronic kidney disease (GFR 30 mL/min) is
prescribed digoxin. What is the most critical consideration for dosing and
monitoring?
A. Digoxin is hepatically metabolized, so renal function does not affect dosing.
B. Digoxin is renally eliminated; dose must be reduced and serum levels monitored.
C. Digoxin dose should be increased to achieve therapeutic effect despite renal
impairment.
D. Digoxin is contraindicated in renal impairment; alternative inotropes are required.
Correct Answer: B. Digoxin is renally eliminated; dose must be reduced and serum
levels monitored.
Rationale: Digoxin is primarily excreted unchanged by the kidneys. In renal impairment,
its half-life is prolonged, increasing the risk of toxicity. Therefore, the dose must be
reduced and serum digoxin levels monitored to avoid toxicity. Options A, C, and D are
incorrect because they either ignore renal clearance or suggest inappropriate actions.
Why Wrong:
A - Digoxin is not hepatically metabolized to a significant extent; renal excretion is
primary.
C - Increasing the dose in renal impairment would dangerously elevate serum levels.
D - Digoxin is not contraindicated; it can be used with dose adjustment.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 37
Q5. Which of the following drug combinations is most likely to cause a fatal serotonin
syndrome?
Page 4
250 Verified Questions
NR 565 Midterm Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study resource provides 250 verified questions and answers for the NR 565
Midterm Exam in Advanced Pharmacology Fundamentals at Chamberlain University. Designed for the
2026/2027 academic year, it covers essential pharmacological principles, drug classifications, and
clinical applications. Each question is aligned with current guidelines and evidence-based practice to
ensure exam readiness. This document is an indispensable tool for nursing students aiming to excel in
their midterm assessment.
Key Features:
Pharmacokinetics and pharmacodynamics
Drug classifications and mechanisms of action
Prescribing principles and legal/ethical considerations
Special populations (pediatric, geriatric, pregnancy)
Adverse effects, drug interactions, and contraindications
Clinical decision-making and patient education
Updates for 2026:
- Updated to reflect 2026-2027 curriculum changes
- Revised to include latest FDA drug approvals and warnings
- Enhanced rationales with evidence-based explanations
- Added new questions on emerging pharmacotherapies
- Aligned with current Chamberlain University exam blueprint
Abstract:
This meticulously curated exam preparation document offers 250 verified questions and answers for the NR 565
Midterm Exam, focusing on Advanced Pharmacology Fundamentals. The content is structured to reinforce core
pharmacological concepts, including drug absorption, distribution, metabolism, and excretion, as well as receptor
theory and dose-response relationships. It delves into major drug classes affecting the autonomic nervous system,
cardiovascular, respiratory, endocrine, and central nervous systems, with emphasis on clinical application and
prescribing principles. Special attention is given to high-risk populations, such as pregnant women, pediatric, and
geriatric patients, and the legal and ethical responsibilities of advanced practice nurses. Each question is
accompanied by a detailed rationale explaining the correct answer and why distractors are incorrect, facilitating
deeper understanding and retention. The document is updated to reflect the latest evidence-based guidelines and
drug information, ensuring alignment with current practice standards. This resource is an essential study aid for
nursing students seeking to pass the NR 565 midterm with confidence and achieve a high level of pharmacological
competence.
Keywords:
Advanced Pharmacology, NR 565, Chamberlain University, Midterm Exam, Nursing Pharmacology, Drug
Interactions, Prescribing, Pharmacokinetics
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a comprehensive rationale explaining the pharmacological basis and clinical reasoning. Distractor
explanations are provided to clarify common misconceptions and reinforce key concepts.
Page 1
,Compliance Checklist:
Aligned with Chamberlain University NR 565 course objectives
Updated for 2026-2027 academic year
Based on current clinical practice guidelines
Includes rationales for all answers
Verified for accuracy by pharmacology experts
Suitable for self-assessment and exam preparation
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-50 ADME, receptor theory, dose-response, drug 20%
Pharmacodynamics interactions
Autonomic Nervous System 51-90 Cholinergic, anticholinergic, adrenergic, 16%
Drugs antiadrenergic
Cardiovascular Pharmacology 91-130 Antihypertensives, antiarrhythmics, 16%
diuretics, anticoagulants
Endocrine Pharmacology 131-170 Insulin, oral hypoglycemics, thyroid, 16%
corticosteroids
Central Nervous System Drugs 171-210 Antidepressants, antipsychotics, anxiolytics, 16%
opioids
Special Populations and 211-250 Pediatric, geriatric, pregnancy, legal/ethical, 16%
Prescribing patient education
Page 2
,Q1. A drug is a weak acid with a pKa of 4.4. In the proximal tubule, where urine pH
is 6.4, what is the approximate ratio of ionized to unionized drug, and how does this
affect reabsorption?
A. 10:1, favoring reabsorption
B. 100:1, favoring excretion
C. 1:10, favoring reabsorption
D. 1:100, favoring excretion
Correct Answer: B. 100:1, favoring excretion
Rationale: Using the Henderson-Hasselbalch equation, log(ionized/unionized) = pH - pKa
= 6.4 - 4.4 = 2, so ionized:unionized = 100:1. Ionized drugs are poorly reabsorbed, thus
excretion is favored. Option A reverses the ratio and outcome; C and D use incorrect
ratios.
Why Wrong:
A - Reverses the ratio and incorrectly states reabsorption is favored when ionized.
C - Inverts the ratio and incorrectly suggests reabsorption.
D - Inverts the ratio but correctly identifies excretion, yet the ratio is wrong.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 3
Q2. Which drug is most likely to cause a disulfiram-like reaction when administered
concurrently with metronidazole?
A. Ciprofloxacin
B. Trimethoprim-sulfamethoxazole
C. Ceftriaxone
D. Azithromycin
Correct Answer: C. Ceftriaxone
Rationale: Cephalosporins, particularly those with a methyltetrazolethiol side chain like
ceftriaxone, can cause a disulfiram-like reaction with alcohol. Metronidazole also causes
this reaction. Ciprofloxacin, TMP-SMX, and azithromycin do not have this effect.
Why Wrong:
A - Fluoroquinolones do not have the methyltetrazolethiol side chain and do not cause
disulfiram-like reactions.
B - Sulfonamides are not associated with disulfiram-like reactions.
D - Macrolides are not known to cause disulfiram-like reactions.
Reference: Lexicomp. (2026). Drug Information Handbook, 24th Ed.
Q3. A patient is taking warfarin and is prescribed a course of rifampin for
tuberculosis. How should the warfarin dose be adjusted, and what monitoring is
required?
Page 3
, A. Decrease warfarin dose; monitor INR weekly
B. Increase warfarin dose; monitor INR frequently
C. Maintain warfarin dose; monitor INR monthly
D. Discontinue warfarin; use heparin instead
Correct Answer: B. Increase warfarin dose; monitor INR frequently
Rationale: Rifampin is a potent CYP450 inducer, increasing warfarin metabolism and
reducing its anticoagulant effect. Therefore, the warfarin dose will likely need to be
increased to maintain therapeutic INR, with frequent monitoring to guide adjustments.
Decreasing or maintaining the dose would risk subtherapeutic anticoagulation.
Why Wrong:
A - Decreasing the dose would further reduce anticoagulation, increasing clot risk.
C - Maintaining the dose without adjustment would lead to subtherapeutic INR due to
increased metabolism.
D - Discontinuing warfarin is not necessary; dose adjustment is standard.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 30
Q4. A patient with heart failure and chronic kidney disease (GFR 30 mL/min) is
prescribed digoxin. What is the most critical consideration for dosing and
monitoring?
A. Digoxin is hepatically metabolized, so renal function does not affect dosing.
B. Digoxin is renally eliminated; dose must be reduced and serum levels monitored.
C. Digoxin dose should be increased to achieve therapeutic effect despite renal
impairment.
D. Digoxin is contraindicated in renal impairment; alternative inotropes are required.
Correct Answer: B. Digoxin is renally eliminated; dose must be reduced and serum
levels monitored.
Rationale: Digoxin is primarily excreted unchanged by the kidneys. In renal impairment,
its half-life is prolonged, increasing the risk of toxicity. Therefore, the dose must be
reduced and serum digoxin levels monitored to avoid toxicity. Options A, C, and D are
incorrect because they either ignore renal clearance or suggest inappropriate actions.
Why Wrong:
A - Digoxin is not hepatically metabolized to a significant extent; renal excretion is
primary.
C - Increasing the dose in renal impairment would dangerously elevate serum levels.
D - Digoxin is not contraindicated; it can be used with dose adjustment.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 37
Q5. Which of the following drug combinations is most likely to cause a fatal serotonin
syndrome?
Page 4
